{"entity":{"id":"nct07285694","kind":"trial","name":"AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)","aka":[],"tldr":"A phase 1/2 trial of AB-3028 in prostate cancer, run by Arsenal Biosciences, Inc., active and no longer recruiting.","summary":"AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC) is a phase 1/2 interventional study registered as NCT07285694 by Arsenal Biosciences, Inc., with 190 participants enrolled, started 2026-01-09 and due to reach its primary completion in 2029-05. Interventions recorded: AB-3028.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07285694","url":"https://clinicaltrials.gov/study/NCT07285694"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["arsenal-bio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07285694","phase":"1/2","setting":"An Open-label, Multicenter Phase 1/2 Study to Evaluate the Safety and Efficacy of AB-3028 in Patients With Castration Resistant Prostate Cancer (CRPC)","sponsor":"Arsenal Biosciences, Inc.","enrolled":190,"outcomes":[]},"route":"/trials/nct07285694/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"company":[{"id":"arsenal-bio","kind":"company","name":"Arsenal Biosciences","route":"/companies/arsenal-bio/"}]}}